Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | CFO | March 29, 2021 | April 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date March 29, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,633 |
Reported balance
After 2021-03-29 transaction · row 1
1 source rowRow 1 · 2021-03-29 · Grant · Acquired 11,250 · Balance 54,633 F1: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2031-03-29 | Direct | 67,500 |
Reported balance
After 2021-03-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-29 · Grant · Acquired 67,500 · Balance 67,500 F2: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025.
F2: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 20, 2024
Section 16 reporting ended · disclosed 2024-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
1 source rowRow 1 · 2024-02-19 · Other · Disposed 39,367 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 376,590 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.06 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-19 · Disposition to issuer · Disposed 97,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.55 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-19 · Disposition to issuer · Disposed 74,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74,500 | Not disclosed Strike: $17.55 | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · derivative · entry 6 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,500 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 97,500 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · derivative · entry 5 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,500 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash from Parent, if and when payments in respect of CVRs are required to be made, equal to the product obtained by multiplying (a) the aggregate number of shares underlying such option immediately prior to the Effective Time by (b) the amount by which (1) the sum of $15.00 plus the aggregate amount paid per CVR exceeds (2) the exercise price of such stock option. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $9.06 | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · derivative · entry 4 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 376,590 | Not disclosed Strike: $7.44 | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · derivative · entry 3 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 376,590 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · derivative · entry 2 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | OtherCommon Stock | 39,367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017410 · ownership.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 18:26 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 4,430 | $15.47 | $68,509.95 |
DisclosureSEC source: 0001209191-23-059623 · doc4.xml · nonDerivative · entry 2 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,037 F3 · shares: Reflects shares sold to cover taxes arising upon accelerated vesting of restricted stock unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.46 to $15.48. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 18:26 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 10,753 | $15.46 | $166,210.20 |
DisclosureSEC source: 0001209191-23-059623 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,467 F1 · shares: Reflects shares sold to cover withholding taxes upon accelerated vesting of restricted stock unit awards pursuant to a Rule10b5-1 instruction letter dated December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $15.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:28 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 3,066 | $8.86 | $27,169.36 |
DisclosureSEC source: 0001209191-23-044084 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,620 F1 · shares: Reflects shares sold to cover withholding taxes upon vesting of restricted stock unit awards pursuant to a Rule 10b5-1 instruction letter dated December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.71 to $9.11. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 19:16 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001209191-23-010917 · doc4.xml · derivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 15, 2024, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 20:04 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 1,902 | $10.69 | $20,337.33 |
DisclosureSEC source: 0001209191-23-009913 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,686 F1 · shares: Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $11.02. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 19:05 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-22-056838 · doc4.xml · derivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-11-09 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on each of the first three anniversaries of November 10, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 21:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 495 | $6.70 | $3,318.38 |
DisclosureSEC source: 0001209191-22-044023 · doc4.xml · nonDerivative · entry 3 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,921 F1 · shares: Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.460 to $6.865. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 21:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 1,825 | $6.64 | $12,113.26 |
DisclosureSEC source: 0001209191-22-044023 · doc4.xml · nonDerivative · entry 2 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,416 F1 · shares: Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.38 to $7.17. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:43 UTC | Icosavax, Inc. ICVX · Entity 94107 | SaleCommon Stock | 639 | $7.11 | $4,541.76 |
DisclosureSEC source: 0001209191-22-044023 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,241 F1 · shares: Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.93 to $7.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 31, 2022 Filed Feb 14, 2023 17:22 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 1,667 | $5.77 | $9,618.59 |
DisclosureSEC source: 0001209191-23-009262 · doc5.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,588 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022 by the Reporting person in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:08 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 74,500 | $0.00 Strike: $17.55 | $0.00 |
DisclosureSEC source: 0001209191-22-009522 · doc4.xml · derivative · entry 2 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,500 Underlying: Common Stock · 74,500 shares Expires 2032-02-09 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 10, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:08 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 17,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009522 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,880 F1 · shares: Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 10, 2022, subject to the reporting persons continued service through the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date. F2 · balance_after: Includes 1,666 shares acquired under the Issuer's employee stock purchase plan on November 30, 2021. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 21:19 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 32,500 | $15.00 | $487,500.00 |
DisclosureSEC source: 0000899243-21-031136 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Represents restricted stock units ("RSUs") granted on July 30, 2021, 25% of the total number of RSUs granted vest on each of the first four anniversaries of July 28, 2021, the vesting commencement date, subject to the reporting person's continued service on the applicable vesting date. Vesting of the RSUs shall accelerate as provided in the reporting person's offer letter. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 29, 2021 Filed Apr 2, 2021 20:41 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001209191-21-024636 · doc4.xml · derivative · entry 2 Russo Thomas Joseph · CIK 0001791973 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2031-03-29 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025. Read SEC document |
| March 29, 2021 Filed Apr 2, 2021 20:41 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024636 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,633 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 20:14 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 43,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021797 · doc4.xml · nonDerivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,383 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2021; March 29, 2022; March 29, 2023, and March 29, 2024. Read SEC document |
| October 28, 2019 Filed Oct 28, 2019 22:51 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $15.69 | $0.00 |
DisclosureSEC source: 0001209191-19-054274 · doc4.xml · derivative · entry 1 Russo Thomas Joseph · CIK 0001791973 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2019-10-28 F1 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, October 28, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on October 28, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.